[HTML][HTML] Thalidomide in the treatment of leprosy

…, KE Resztak, MA Scheffler, KA Kook, JB Zeldis… - Microbes and …, 2002 - Elsevier
Leprosy is a chronic infection of the skin and nerves caused by Mycobacterium leprae.
Erythema nodosum leprosum (ENL) is a reactive state in lepromatous leprosy. Thalidomide has …

The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro

…, EK Mantlo, RA Sattler, C Huang, S Paessler, J Zeldis - BioRxiv, 2020 - biorxiv.org
The ongoing COVID-19 pandemic continues to pose a major public health burden around
the world. The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-…

[HTML][HTML] A Randomized, Double-Blind, Placebo-Controlled Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone Alone as Primary Therapy for Newly …

…, S Sirkovich, M Olesnyckyj, Z Yu, R Knight, J Zeldis… - Blood, 2006 - Elsevier
Purpose: Updated results, including response rate data, from a randomized, double-blind,
placebo-controlled study comparing thalidomide plus dexamethasone versus dexamethasone …

[HTML][HTML] An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups …

JD Shaughnessy Jr, J Haessler, J Zeldis, Y Huang… - Blood, 2006 - Elsevier
Background: THAL, whose activity in MM was discovered in the setting of advanced and
refractory disease in the late 1990's (Singhal, NEJM, 2000), has become the standard front-line …

[HTML][HTML] Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell …

…, N Bell, C Byrne, P Weaver, K Hartig, R Knight, J Zeldis… - Blood, 2007 - Elsevier
… Knight and Jerry Zeldis are emplorees of Celgene and have ownership interests (including
stock options).; Neda Bell, Catriona Byrne, Robert Knight and Jerry Zeldis are emplorees of …

Phase II Trial of Oblimersen Sodium (G3139), Dexamethasone (Dex) and Thalidomide (Thal) in Relapsed Multiple Myeloma Patients (Pts).

…, A Rapoport, J Bolaños-Meade, B Zhang, J Zeldis… - Blood, 2004 - Elsevier
Bcl-2 acts as an important regulator of the mitochondrial pathway of apoptosis and promotes
resistance of MM cells to chemotherapy. The Bcl-2 antisense oligonucleotide G3139 …

A Pharmacokinetic & Pharmacodynamic Study of Oral Lenalidomide in Patients with Low-or Intermediate-1-Risk Myelodysplastic Syndromes.

A Wu, A List, R Lush, K Bretz, R Knight, J Zeldis, H Lau - 2006 - ashpublications.org
Twelve patients diagnosed with low- or intermediate-1-risk myelodysplastic syndromes (MDS)
were administered a single, 10 mg dose of lenalidomide followed by 24-hour blood and …

The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro.(preprint)

…, EK Mantlo, RA Sattler, C Huang, S Paessler, J Zeldis - 2020 - pesquisa.bvsalud.org
The ongoing COVID-19 pandemic continues to pose a major public health burden around
the world. The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-…

Zhinuan Yu, Robert Knight, Jerry Zeldis, Joan Blade Hematology, Mayo Clinic, Rochester, MN, USA; Hematology, Cleveland Clinic, Cleveland, OH; Frankston Hospital …

SV Rajkumar, M Hussein, J Catalano, W Jedrzejcak… - researchgate.net
Purpose: Updated results, including response rate data, from a randomized, double-blind,
placebo-controlled study comparing thalidomide plus dexamethasone versus dexamethasone …

[BOOK][B] Molecular characterization of the rhesus cytomegalovirus genome

RH Kravitz - 1998 - search.proquest.com
Cytomegalovirus, while relatively non-pathogenic in an immunocompetent host, is a significant
cause of morbidity and mortality in the immunocompromised individual. Persons at risk …